stoxline Quote Chart Rank Option Currency Glossary
  
Zentalis Pharmaceuticals, Inc. (ZNTL)
9.52  -0.27 (-2.76%)    06-13 16:00
Open: 9.71
High: 9.92
Volume: 698,017
  
Pre. Close: 9.79
Low: 9.48
Market Cap: 676(M)
Technical analysis
2024-06-13 4:47:27 PM
Short term     
Mid term     
Targets 6-month :  13.78 1-year :  15.46
Resists First :  11.8 Second :  13.23
Pivot price 11.05
Supports First :  9.47 Second :  7.88
MAs MA(5) :  10.07 MA(20) :  11.26
MA(100) :  12.84 MA(250) :  17.17
MACD MACD :  -0.6 Signal :  -0.5
%K %D K(14,3) :  4.7 D(3) :  7.8
RSI RSI(14): 28.2
52-week High :  30.53 Low :  9.47
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ZNTL ] has closed above bottom band by 0.1%. Bollinger Bands are 1.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.98 - 10.08 10.08 - 10.14
Low: 9.28 - 9.4 9.4 - 9.48
Close: 9.38 - 9.58 9.58 - 9.7
Company Description

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

Headline News

Thu, 13 Jun 2024
We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely - Simply Wall St

Thu, 13 Jun 2024
Birchview Capital LP Purchases New Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Thu, 13 Jun 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Sets New 12-Month Low at $9.48 - MarketBeat

Wed, 12 Jun 2024
Verition Fund Management LLC Sells 192,742 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - MarketBeat

Wed, 12 Jun 2024
Verition Fund Management LLC Sells 192742 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) - Defense World

Tue, 04 Jun 2024
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 71 (M)
Shares Float 52 (M)
Held by Insiders 3.7 (%)
Held by Institutions 120.7 (%)
Shares Short 18,530 (K)
Shares Short P.Month 16,640 (K)
Stock Financials
EPS -3.26
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.46
Profit Margin 0 %
Operating Margin -61.1 %
Return on Assets (ttm) -25 %
Return on Equity (ttm) -51.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.57
EBITDA (p.s.) -2.93
Qtrly Earnings Growth 0 %
Operating Cash Flow -211 (M)
Levered Free Cash Flow -75 (M)
Stock Valuations
PE Ratio -2.93
PEG Ratio 0
Price to Book value 1.47
Price to Sales 16.66
Price to Cash Flow -3.22
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android